Entero Therapeutics Statistics
Total Valuation
ENTO has a market cap or net worth of $1.32 million. The enterprise value is $66.60 million.
Important Dates
The next estimated earnings date is Wednesday, November 20, 2024, before market open.
| Earnings Date | Nov 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ENTO has 3.25 million shares outstanding. The number of shares has increased by 1,078.55% in one year.
| Shares Outstanding | 3.25M |
| Shares Change (YoY) | +1,078.55% |
| Shares Change (QoQ) | +1,758.44% |
| Owned by Insiders (%) | 2.16% |
| Owned by Institutions (%) | 4.69% |
| Float | 3.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.05 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.21 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -262.73 |
Financial Efficiency
Return on equity (ROE) is -15.28% and return on invested capital (ROIC) is -29.67%.
| Return on Equity (ROE) | -15.28% |
| Return on Assets (ROA) | -27.07% |
| Return on Capital (ROIC) | -29.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$715,952 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -14.86M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.56% in the last 52 weeks. The beta is 1.37, so ENTO's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | -93.56% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 2.76 |
| Relative Strength Index (RSI) | 49.08 |
| Average Volume (20 Days) | 748,269 |
Short Selling Information
The latest short interest is 127,317, so 3.91% of the outstanding shares have been sold short.
| Short Interest | 127,317 |
| Short Previous Month | 76,379 |
| Short % of Shares Out | 3.91% |
| Short % of Float | 4.00% |
| Short Ratio (days to cover) | 0.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.93M |
| Pretax Income | -21.02M |
| Net Income | -6.44M |
| EBITDA | -20.90M |
| EBIT | -20.93M |
| Earnings Per Share (EPS) | -$8.61 |
Full Income StatementBalance Sheet
The company has $3.43 million in cash and $6.98 million in debt, giving a net cash position of -$3.55 million or -$1.09 per share.
| Cash & Cash Equivalents | 3.43M |
| Total Debt | 6.98M |
| Net Cash | -3.55M |
| Net Cash Per Share | -$1.09 |
| Equity (Book Value) | 77.86M |
| Book Value Per Share | 7.99 |
| Working Capital | 1.32M |
Full Balance SheetCash Flow
| Operating Cash Flow | -13.28M |
| Capital Expenditures | n/a |
| Free Cash Flow | -13.28M |
| FCF Per Share | -$4.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |